Combined Intra-Arterial and Intravitreal Chemotherapy in Retinoblastoma
A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.11594/ojkmi.v8i1.99Keywords:
Intraarterial, Intravitreal, Chemotherapy, RetinoblastomaAbstract
Introduction: Intra-arterial chemotherapy for retinoblastoma has been widely implemented as a primary or secondary treatment choice, yet its efficacy alone is limited in cases with extensive vitreous seed. The effect of intravitreal chemotherapy combined with intra-arterial chemotherapy on tumor control rates and globe salvage is still uncertain. The objective of this review was to explore the effectiveness and safety of intra-arterial plus intravitreal chemotherapy in retinoblastoma.
Methods: A comprehensive search strategy was implemented across three electronic databases (PubMed, Scopus, and Cochrane) for relevant studies from inception until June 2024.
Results: Six studies involving 471 eyes were included in the analysis,. Only three studies were comparative. The level of heterogeneity varied across each reported outcomes. The pooled globe salvage rate was 66% (311/471 eyes, 0.78 [95% CI: 0.55, 0.91]). The overall tumor control rate was 83.5% (304/364 eyes, 0.86 [95% CI: 0.74, 0.93]). Metastatic disease occurred in 3 of 471 eyes (0.63%, 0.015 [95% CI: 0.006, 0.036]).
Conclusion: The pooled evidence from this meta-analysis supports the efficacy and favorable safety profile of combined intra-arterial and intravitreal chemotherapy in treating retinoblastoma. Further research with extended follow-up period are needed to validate these findings.
Downloads
References
Nag A, Khetan V. Retinoblastoma – A comprehensive review, update and recent advances. Indian J Ophthalmol. 2024 June;72(6):778–88.
Global Retinoblastoma Study Group, Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, et al. Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncol. 2020 May 1;6(5):685–95.
Schaiquevich P, Francis JH, Cancela MB, Carcaboso AM, Chantada GL, Abramson DH. Treatment of Retinoblastoma: What Is the Latest and What Is the Future. Front Oncol. 2022 Apr 1;12:822330.
Raval V, Bowen RC, Soto H, Singh A. Chemotherapy for Retinoblastoma: Impact of Intravitreal Chemotherapy. Asia-Pac J Ophthalmol. 2021 Mar 1;10(2):200–2.
Ja C, J G, G K, M R, A GL, A G, et al. Intra-arterial chemotherapy for retinoblastoma. PubMed [Internet]. [cited 2024 July 12]; Available from: https://pubmed.ncbi.nlm.nih.gov/35584909/
Sen M, Rao R, Mulay K, Reddy VAP, Honavar SG. Intravitreal topotecan for vitreous seeds in retinoblastoma: A long-term review of 91 eyes. Ophthalmology [Internet]. 2024 May 3 [cited 2024 June 7]; Available from: https://www.sciencedirect.com/science/article/pii/S0161642024002768
Lavasidis G, Strongylis M, Tzamalis A, Tsinopoulos I, Ntzani EE. Safety of intravitreal chemotherapy in the management of retinoblastoma: A systematic review of the literature. Crit Rev Oncol Hematol. 2024 Aug 1;200:104423.
Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol. 2020 Nov;68(11):2356.
Daniels AB, Patel SN, Milam RW, Kohanim S, Friedman DL, Koyama T. Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class—A Meta-Analysis. Cancers. 2021 Jan;13(9):2216.
Martínez Arce CA, Villegas VM, Di Nicola M, Williams BK, Murray TG. Update on Retinoblastoma Therapies. Medicina (Mex). 2025 July 4;61(7):1219.
Das A, Saiteja K, Shah PK, Prema S, Narendran V. Outcomes and adverse events following intra-arterial chemotherapy for retinoblastoma: A single center study in South India. World J Clin Pediatr. 2025 Sept 9;14(3):103732.
Gupta AK, Meena JP. A narrative review of retinoblastoma and recent advances in its management. Pediatr Med [Internet]. 2020 Nov 30 [cited 2026 Jan 12];3(0). Available from: https://pm.amegroups.org/article/view/5703/html
Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014 July;121(7):1453–60.
Shields CL, Alset AE, Say EAT, Caywood E, Jabbour P, Shields JA. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era. J Pediatr Ophthalmol Strabismus. 2016 Sept;53(5):275–84.
Naseripour M, Sedaghat A, Mirshahi R, Abdolalizadeh P, Koushki A, Faranoush M, et al. Targeted chemotherapy in retinoblastoma: A step forward from patient survival to globe survival. Eur J Ophthalmol [Internet]. 2022 Apr 13 [cited 2025 Feb 4]; Available from: https://journals.sagepub.com/doi/full/10.1177/11206721221093018
Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran (PNPK) Tatalaksana Retinoblastoma. Jakarta; 2022. 42–4 p.
Shields CL, Alset AE, Say EAT, Caywood E, Jabbour P, Shields JA. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era. J Pediatr Ophthalmol Strabismus. 2016 Sept 1;53(5):275–84.
Schaiquevich P, Francis JH, Cancela MB, Carcaboso AM, Chantada GL, Abramson DH. Treatment of Retinoblastoma: What Is the Latest and What Is the Future. Front Oncol. 2022 Apr 1;12:822330.
Chen Q, Zhang B, Dong Y, Mo X, Zhang L, Huang W, et al. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. BMC Cancer. 2018 Apr 27;18(1):486.
Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014 Mar;98(3):292–7.
Francis JH, Iyer S, Gobin YP, Brodie SE, Abramson DH. Retinoblastoma Vitreous Seed Clouds (Class 3): A Comparison of Treatment with Ophthalmic Artery Chemosurgery with or without Intravitreous and Periocular Chemotherapy. Ophthalmology. 2017 Oct;124(10):1548–55.
Yousef YA, Soliman SE, Astudillo PPP, Durairaj P, Dimaras H, Chan HSL, et al. Intra-arterial Chemotherapy for Retinoblastoma: A Systematic Review. JAMA Ophthalmol. 2016 May 1;134(5):584–91.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Oftalmologi Jurnal Kesehatan Mata Indonesia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a 